Kai Lin
Chief Scientific Officer HEC Pharm
Seminars
Wednesday 20th August 2025
Yinfenidone (HEC585): A Promising New Drug Candidate for the Treatment of Pulmonary Fibrosis
12:10 pm
- A potential best-in-class drug candidate that is >100-fold more potent than pirfenidone in vitro and has longer half-life allowing once daily dosingÂ
- Preliminary results from a Phase 2 clinical study in IPF patients showed more pronounced effect on FVC at 24 weeks with improved safety and tolerabilityÂ
- Key preclinical and clinical data will be presented for the first time
